Moving to protect a lucrative monopoly against impending competition, Amgen has reached an agreement that will preserve its status as the main supplier of anemia drugs to one of the nation's two large kidney dialysis chains. Source - http://feeds.nytimes.com/click.phdo?i=b83ea579d7fa8e486860dd83596b7c81
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন